Jason Roszik

20.2k total citations · 1 hit paper
177 papers, 5.5k citations indexed

About

Jason Roszik is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Jason Roszik has authored 177 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Oncology, 72 papers in Molecular Biology and 46 papers in Cancer Research. Recurrent topics in Jason Roszik's work include Cancer Immunotherapy and Biomarkers (32 papers), Cancer Genomics and Diagnostics (29 papers) and Immunotherapy and Immune Responses (28 papers). Jason Roszik is often cited by papers focused on Cancer Immunotherapy and Biomarkers (32 papers), Cancer Genomics and Diagnostics (29 papers) and Immunotherapy and Immune Responses (28 papers). Jason Roszik collaborates with scholars based in United States, Hungary and Australia. Jason Roszik's co-authors include Patrick Hwu, Elizabeth A. Grimm, Scott E. Woodman, P. Andrew Futreal, Chantale Bernatchez, Lisa Maria Mustachio, Jennifer A. Wargo, Yong Qin, Padmanee Sharma and Vivek Subbiah and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Jason Roszik

171 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

2016 913 citations Jason Roszik, Chantale Bernatchez et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason Roszik United States	38	2.6k	2.3k	1.9k	1.2k	799	177	5.5k
James S. Wilmott Australia	36	4.4k 1.7×	2.8k 1.2×	2.4k 1.3×	798 0.7×	1.0k 1.3×	139	6.4k
Christine Solbach Germany	36	3.1k 1.2×	1.5k 0.7×	1.2k 0.6×	1.6k 1.3×	715 0.9×	140	5.3k
Johan Botling Sweden	39	1.6k 0.6×	2.8k 1.2×	1.1k 0.6×	1.2k 1.0×	1.1k 1.3×	117	5.3k
Christina M. Annunziata United States	37	2.6k 1.0×	2.5k 1.1×	1.2k 0.6×	1.0k 0.8×	531 0.7×	155	5.4k
Mitchell P. Levesque Switzerland	40	2.1k 0.8×	3.4k 1.5×	1.3k 0.7×	705 0.6×	450 0.6×	167	5.8k
Jaime Rodriguez‐Canales United States	44	2.9k 1.1×	2.7k 1.2×	1.3k 0.7×	1.7k 1.4×	1.3k 1.6×	163	6.8k
Paola Queirolo Italy	44	5.3k 2.1×	3.0k 1.3×	2.5k 1.3×	662 0.5×	951 1.2×	233	7.3k
Giuseppe Palmieri Italy	39	3.1k 1.2×	3.0k 1.3×	1.0k 0.5×	1.2k 1.0×	758 0.9×	259	6.2k
Zachary A. Cooper United States	34	2.6k 1.0×	2.6k 1.1×	1.3k 0.7×	623 0.5×	473 0.6×	77	4.8k
Toshihiro Yamaguchi Japan	28	1.7k 0.7×	3.6k 1.6×	1.9k 1.0×	1.8k 1.5×	728 0.9×	124	6.7k

Countries citing papers authored by Jason Roszik

Since Specialization

Citations

This map shows the geographic impact of Jason Roszik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Roszik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Roszik more than expected).

Fields of papers citing papers by Jason Roszik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Roszik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Roszik. The network helps show where Jason Roszik may publish in the future.

Co-authorship network of co-authors of Jason Roszik

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Roszik. A scholar is included among the top collaborators of Jason Roszik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Roszik. Jason Roszik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goldberg, Jonathan, Jennifer L. Guerriero, Anne V. Philips, et al.. (2024). Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor–positive Breast Cancer. Cancer Research Communications. 4(2). 496–504. 7 indexed citations

Yuan, Ping, Da Teng, Man Li, et al.. (2023). Loss of AMPKα2 promotes melanoma tumor growth and brain metastasis. iScience. 26(6). 106791–106791. 9 indexed citations

Ghosh, Susmita, Fan Fan, Reid T. Powell, et al.. (2023). Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer. Molecular Cancer Therapeutics. 22(8). 962–975. 5 indexed citations

Subbiah, Vivek, Niamh Coleman, Sarina A. Piha‐Paul, et al.. (2023). Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Research Communications. 4(2). 378–387. 16 indexed citations

Nelson, Blessie Elizabeth, Jason Roszik, Filip Jankú, et al.. (2023). BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. npj Precision Oncology. 7(1). 19–19. 16 indexed citations

Roszik, Jason, J. Jack Lee, Yu‐Hung Wu, et al.. (2022). Real-world Studies Link NSAID Use to Improved Overall Lung Cancer Survival. Cancer Research Communications. 2(7). 590–601. 3 indexed citations

Prudner, Bethany C., Richa Rathore, Katharine E. Caldwell, et al.. (2022). Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102. Clinical Cancer Research. 28(16). 3573–3589. 19 indexed citations

Chattopadhyay, Chandrani, Rajat Bhattacharya, Jason Roszik, et al.. (2022). Targeting IRS-1/2 in Uveal Melanoma Inhibits In Vitro Cell Growth, Survival and Migration, and In Vivo Tumor Growth. Cancers. 14(24). 6247–6247. 6 indexed citations

Sarshekeh, Amir Mehrvarz, Jason Roszik, Ganiraju C. Manyam, et al.. (2021). ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clinical Cancer Research. 27(6). 1663–1670. 40 indexed citations

10.

Kawakami, Masanori, Lisa Maria Mustachio, Yulong Chen, et al.. (2020). A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. Molecular Cancer Therapeutics. 20(3). 477–489. 13 indexed citations

11.

Williams, Leila J., Courtney W. Hudgens, Grant M. Fischer, et al.. (2020). The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies. Molecular Cancer Therapeutics. 20(3). 500–511. 112 indexed citations

12.

Adashek, Jacob J., Jason Roszik, Arjun K. Menta, et al.. (2020). Cancer Genetics and Therapeutic Opportunities in Urologic Practice. Cancers. 12(3). 710–710. 4 indexed citations

13.

Villar‐Prados, Alejandro, Sherry Y. Wu, Karem A. Court, et al.. (2018). Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. Molecular Cancer Therapeutics. 18(2). 421–436. 10 indexed citations

14.

Ritthipichai, Krit, Cara Haymaker, Xiaohui Yi, et al.. (2017). Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter. Clinical Cancer Research. 23(20). 6151–6164. 54 indexed citations

15.

Park, Jungsun, Amjad H. Talukder, Seon Ah Lim, et al.. (2017). SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity. Cancer Immunology Research. 5(8). 618–629. 24 indexed citations

16.

Harao, Michiko, Marie-Andrée Forget, Jason Roszik, et al.. (2017). 4-1BB–Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells. Cancer Immunology Research. 5(6). 439–445. 49 indexed citations

17.

Mustachio, Lisa Maria, Yun Lu, Laura J. Tafe, et al.. (2017). Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer. Molecular Cancer Research. 15(7). 905–914. 34 indexed citations

18.

Qin, Yong, Jason Roszik, Chandrani Chattopadhyay, et al.. (2016). Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Molecular Cancer Therapeutics. 15(10). 2442–2454. 41 indexed citations

19.

Sim, Geok Choo, Chengwen Liu, Ena Wang, et al.. (2016). IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation. Cancer Immunology Research. 4(11). 983–994. 36 indexed citations

20.

Wilson, Melissa, Fengmin Zhao, Sanika Khare, et al.. (2015). Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clinical Cancer Research. 22(2). 374–382. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact